GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Kidney stones cause a range of symptoms as they pass from the kidneys out of the body through the urethra. Learn about pain, ...

Gender-affirming care available during Donald Trump’s administration could be defunded if he’s reelected. Trans voices share concerns.

The national HIV prevalence was 16.3% among adults aged 15 years and older, translating to an estimated 7.4 million adults ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...